Replies to post #268928 on Avid Bioservices Inc (CDMO)

[jakedogman1]

All the more reason the get the tech into much more capable hands with the resources to get clinical results. Will mgmt slow play it like they have in order to get more cheap shares at the expense of current shareholders? IMO mgmt has not acted as fiduciaries in creating value for shareholders. If the proxy comes out with the same useless BOD, shareholders need to get united and demand change.

[sulaco]

OK, Ex, did you actually read the studies you posted

None of them uses adjuvant hormonal therapy in combination with downstream 1.0 inhibitors.

Not one.

Yes, there is one study with HER2+ positive receptor breast cancer, but no mention of Herceptin (which is a limited field anyway as only 20% of breast cancers express this gene receptor.)

Ditto for all the others. No tamoxifen, no Xtandi. No Herceptin.